So proud of John who was selected for a talk after his year in the lab and presented along faculty and post docs. His next stop, medical school! #proudPI ⁦CU Anschutz Medical Campus⁩

TODAY TODAY Thursday, April 18th | 12:00 MT

Lunchtime education | Free virtual CE event:
Robert H. Allen, MD Memorial Hematology Symposia bit.ly/CUHemeSymposia……

Registration is required.

Wow - terrific to see Colorado's Dr. Buckner on #WorldHemophiliaDay ! 💟🩸🌄

I guess I’ve entered full PI mode as I no longer know where things are in the lab.. 🧫👩🏻‍🔬🤷🏻‍♀️ #NewPI

Congratulations to first year fellow Aaron Lee, DO. Dr. Lee has been accepted to the DOM Leaders in Informatics, Quality, & Systems (LInQs) Fellowship Cohort 6 for Academic Year 2024-2026. #CUAnschutz #CUCancer #CUDeptMedicine

Thursday, April 18th - NEXT WEEK | 12:00 MT

Please join for a free virtual CE Event!

Robert H. Allen, MD Memorial Hematology Symposia
bit.ly/CUHemeSymposia…

Registration is required.

Want a comprehensive overview of the FDA-approved CD19 #CART products & CD20 bispecifics available for #DLBCL and an insight into their optimal sequencing?

Watch our wonderful interview with manalikamdar (@CUCancerCenter):

👉 ow.ly/YNcy50R7mwE

#LYMsm #Lymphoma #HemOnc

Our very own Dr. manalikamdar is featured over on the CU Anschutz Medical Campus Instagram page giving advice to young women interested in a career in medicine: instagram.com/reel/C5HVWYwLb… cc CU School of Medicine CU Anschutz Division of Hematology #WomensHistoryMonth

Join our dream 💭 team!
Hetty Carraway
Daniel Pollyea
Kelly Bolton MD PhD
Dr. Uma Borate: Associate Professor
Pinkal Desai
Amy DeZern
John F. DiPersio Lab
AK Eisfeld
Marcela Ferrada
G Garcia-Manero
Siddhartha Jaiswal

👉 ms.spr.ly/6015clFLv
#ALFlive24

Of course we have branded gear for our BISON-PRO Quality of Life Study! We're collecting longitudinal patient-reported outcomes surveys from folks with blood disorders CU Anschutz Medical Campus uchealth. Learn more about the CU Cancer Center study at bison-pro.org. #qualityoflife

Reminder to come support Lorraine Davis in the Daniel Sherbenou, MD, PhD lab tomorrow at 10 am for her thesis defense! #BestYouCANB

For all you #lymsm nerds (and heme/onc fellows!) out there, check out our #ASH23 Education Program review on how we sequence CAR-T and bispecific antibody therapies in R/R aggressive NHLs. We prefer CAR-T for almost all patients if available. #onctwitter
ashpublications.org/hematology/art…

Check out the new article CU Anschutz Medical Campus featuring our CU Lymphoma Program faculty Drs. manalikamdar & Ajay Major, MD, MBA about their ASH 2023 Education Program review on CAR-T versus bispecific antibodies in relapsed aggressive lymphomas. #lymsm #ASH23 news.cuanschutz.edu/cancer-center/…

Whohoo!

And ofcourse the wonderful Ernst Laboratory !

The honor was ours! Thank you for joining us in Denver, Colorado @ 2024 Denver ASH Review. 💟🩸

Today at CU Anschutz Division of Hematology Denver ASH Review: Brad Haverkos presenting better PFS and less deaths with N-AVD in older adults on S1826, and PD1 CPI before ASCT in r/r cHL➡️better PFS. #lymsm

Ruxolitinib in T-LGL #DenverASHReview :
- 23 pts, median LOT 2, 52% STAT3mut
- ORR 48% (better CBR)
- phenom EFS if STAT3mut (duh)
- per Brad Haverkos, not planning to use in the 1L setting but great option in r/r setting #lymsm

Lacutamab (KIR3DL2) in Sezary syndrome #DenverASHReview :
- ORR 38%, better skin/blood responses
- all had previous moga
- median time to response ~3 mos, median DOR 1 year #lymsm #ctcl

AFM13-complexed NK product for R/R CD30+ cHL at #DenverASHReview : 42 pts, no CRS/ICANS or GVH, ORR 97% (78% CR!), most of which had previous BV. DOR still not great due to NK persistence issues, but very promising early-phase data. #lymsm cc Brad Haverkos